Green light for imaging drug
US advisers have recommended approval of a Bayer AG imaging drug for use with magnetic resonance imaging scans of the central nervous system, writes Reuters.
A Food and Drug Administration (FDA) advisory panel voted 16 to zero in favour of the drug, gadobutrol. The FDA usually follows panel recommendations. A final decision is due by 14 March.
Gadobutrol is a stronger version of products in a class called gadolinium-based contrast agents, or GBCAs, used with MRI scans. The drugs carry warnings about the risk of nephrogenic systemic fibrosis, a potentially fatal skin disorder.
Consumer apathy hits photo printing
The a new survey has confirmed what many people in the photo retailing industry have been aware of for some time - and that's consumer apathy when it comes to printing photos, reports Photo & Imaging.
US research firm InfoTrends' recently released Photo Printing End-User Survey has revealed that there is a widespread lack of understanding of the archival benefits of printed photos.
Survey results show that while photo printing remains a vital component of the digital imaging ecosystem, communicating the message on the long-term sustainability of photo prints could give the market more staying power. The survey revealed that many consumers have little understanding of the long-term viability of the various photo storage options that are available.
Coronary imaging identifies heart diseases
Identifying plaques before they cause heart disease may be possible using coronary imaging, a US researcher says, reveals UPI.com.
Dr Gregg Stone of the New York-Presbyterian Hospital/Columbia University Medical Centre says a new clinical trial using multi-modality imaging has provided new insights into atherosclerosis and revealed the type of lesions that place patients at risk of unexpected heart attacks.
These are characteristics that were invisible to the coronary angiogram but easily identifiable by grayscale intravascular ultrasound.
Share